Consumer's Guide to THR-Beta Agonists for MASH Consumer's Guide to THR-Beta Agonists for MASH Here’s everything you need to know about the only type of medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease.

Thyroid hormone receptor (THR)–beta agonists

are the first FDA-approved drug to treat metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease that occurs when fat buildup causes inflammation and damage.

Back

control the body’s metabolism. In the liver, they stimulate receptors, or attachment sites, called THR-betas. By activating this receptor, less fat is stored in the liver.

Thyroid hormones

Back

THR-beta signaling is reduced, leading to a buildup of fat.

In people who have MASH,

Back

work by activating receptors to “turn on” the THR-beta protein in the liver.

THR-BETA AGONIST DRUGS

Back

Replay

Back

helps reduce fat buildup in the liver, lower inflammation, reduce scarring, and prevent further liver damage — and help new, healthy tissue grow.

Activating the THR-beta protein

Back